sibmedСибирский научный медицинский журналСибирский научный медицинский журнал2410-25122410-2520ИЦиГ СО РАН10.18699/SSMJ20240211sibmed-1464Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEМаркеры пролиферации и эпителиально-мезенхимального перехода и их сопряженность с экспрессией мРНК гистидинбогатого гликопротеина HRG при заболеваниях молочной железыCoupling of the expression of proliferation and epithelialmesenchymal transition markers with the histidine-rich glycoprotein HRG mRNA expression in breast diseaseshttps://orcid.org/0000-0002-1390-4426АрхиповС. А.ArkhipovS. А.

Архипов Сергей Алексеевич, д.б.н.

630117, г. Новосибирск, ул. Тимакова, 2;

630091, г. Новосибирск, Красный пр., 52

 

Sergey A. Arkhipov, doctor of biological sciences

630117, Novosibirsk, Timakova st., 2;

630091, Novosibirsk, Krasny ave., 52

arhipowsergei@yandex.ruhttps://orcid.org/0000-0003-3936-1316СтуденикинаА. А.StudenikinaА. А.

Студеникина Анастасия Александровна, к.м.н.

630117, г. Новосибирск, ул. Тимакова, 2;

630091, г. Новосибирск, Красный пр., 52

Anastasia A. Studenikina, candidate of medical sciences

630117, Novosibirsk, Timakova st., 2;

630091, Novosibirsk, Krasny ave., 52

st.aa73@gmail.comhttps://orcid.org/0009-0000-0172-0905АрхиповаВ. В.ArkhipovaV. V.

Архипова Валентина Валериевна

630091, г. Новосибирск, Красный пр., 52

Valentina V. Arkhipova

630091, Novosibirsk, Krasny ave., 52

valia.arkhipova@yandex.ruhttps://orcid.org/0000-0003-2313-1591ПроскураА. В.ProskuraА. V.

Проскура Андрей Викторович, к.м.н.

630117, г. Новосибирск, ул. Тимакова, 2

Andrey V. Proskura, candidate of medical sciences

630117, Novosibirsk, Timakova st., 2

avpdok@ngs.ruhttps://orcid.org/0000-0001-7180-010XАутеншлюсА. И.AutenshlyusА. I.

Аутеншлюс Александр Исаевич, д.б.н., проф.

630117, г. Новосибирск, ул. Тимакова, 2;

630091, г. Новосибирск, Красный пр., 52

Alexander I. Autenshlyus, doctor of biological sciences, professor

630117, Novosibirsk, Timakova st., 2;

630091, Novosibirsk, Krasny ave., 52

lpciip@211.ruНИИ молекулярной биологии и биофизики ФИЦ фундаментальной и трансляционной медицины; Новосибирский государственный медицинский университет Минздрава РоссииРоссияInstitute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine; Novosibirsk State Medical University of Minzdrav of RussiaRussian FederationНовосибирский государственный медицинский университет Минздрава РоссииРоссияNovosibirsk State Medical University of Minzdrav of RussiaRussian FederationНИИ молекулярной биологии и биофизики ФИЦ фундаментальной и трансляционной медициныРоссияInstitute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational MedicineRussian Federation2024270420244429095Copyright © Архипов С.А., Студеникина А.А., Архипова В.В., Проскура А.В., Аутеншлюс А.И., 20242024Архипов С.А., Студеникина А.А., Архипова В.В., Проскура А.В., Аутеншлюс А.И.Arkhipov S.А., Studenikina А.А., Arkhipova V.V., Proskura А.V., Autenshlyus А.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://sibmed.elpub.ru/jour/article/view/1464

Риск развития рака молочной железы возрастает при наличии в анамнезе незлокачественных заболеваний молочной железы (НЗМЖ). Поэтому представляется актуальным поиск критериев малигнизации клеток при НЗМЖ. Цель исследования – изучить сопряженность между экспрессией маркеров пролиферации, эпителиально-мезенхимального перехода (ЭМП) и мРНК гистидинбогатого гликопротеина (HRG) при НЗМЖ. Материал и методы. В биоптатах ткани МЖ 37 больных инвазивной карциномой неспецифического типа (ИКНТ) и 17 пациентов с НЗМЖ иммуногистохимическим методом определяли экспрессию маркеров пролиферации (Ki-67 и циклина (CCND1)), маркеров ЭМП (Е-кадгерина (CDH1), коллагена II типа (CII) и β1-интегрина (CD29)). Экспрессию мРНК HRG оценивали с помощью ПЦР в реальном времени. Результаты. Экспрессия мРНК HRG выявлена при ИКНТ в 91,9 % случаев (34 из 37), при НЗМЖ – в 82,4 % (14 из 17) и в последнем случае находилась в обратной зависимости от экспрессии CDH1, CD29 и Ki-67. Установлена прямая связь между представленностью Ki-67 и CCND1, CII, между CCND1 и CD29 при НЗМЖ. У больных ИКНТ выявлена прямая корреляция между экспрессией мРНК HRG и наличием CII, обратная – между количеством клеток, содержащих CII и CD29. Установлено, что при ИКНТ и НЗМЖ с наличием экспрессии мРНК HRG представленность CDH1 меньше, чем в ее отсутствие. Заключение. Показатели экспрессии мРНК HRG при НЗМЖ в сочетании с оценкой наличия маркеров пролиферации и ЭМП могут быть полезны при разработке критериев вероятностной малигнизации клеток при доброкачественных заболеваниях МЖ.

Non-malignant breast diseases (NMBD) may increase the risk of developing a malignant neoplasm. Therefore, it seems relevant to search for criteria for cell malignancy in NMBD. Aim of the study was to investigate the relationship between expression of proliferation and epithelial-mesenchymal transition (EMT) markers and histidine-rich glycoprotein (HRG) mRNA in breast diseases. Material and methods. In breast biopsy specimens of 37 patients with invasive carcinoma of a non-specific type (ICNT) and 17 patients with NMBD expression of proliferation markers (Ki-67, cyclin D1 (CCND1)) and EMT markers (E-cadherin (CDH1), type II collagen (CII) and β1-integrin (CD29)) was determined immunohistochemically. HRG mRNA expression was estimated using real time PCR. Results. HRG mRNA expression was detected in 91.9 % cases (34 of 37) in ICNT, 82.4 % (14 of 17) in NMBD and in the latter case was inversely related to the expression of CDH1, CD29 and Ki-67. A direct relationship has been established between the presence of Ki-67 and CCND1, CII, between CCND1 and CD29 in NMBD. In patients with ICNT, a direct correlation was found between the HRG mRNA expression and the presence of CII, and an inverse correlation between the number of cells containing CII and CD29. It was found that in ICNT and NMBD with the presence of HRG mRNA expression, the CDH1 expression is less than in its absence. Conclusions. Indicators of HRG mRNA expression in NMBD, combined with the assessment of proliferation and EMT markers, can be useful in developing criteria for cell malignancy in benign breast diseases.

инвазивная карцинома неспецифического типанезлокачественные заболевания молочной железыфиброаденомафиброзно-кистозная болезньHRG4 Ki-67CCND1CDH1CIICD29invasive carcinoma of nonspecific typenon-malignant breast diseasesfibroadenomafibrocystic breast diseaseHRGKi-67CCND1CDH1CIICD29Исследование выполнено в рамках государственного задания (№ АААА-А18-118030790008-7) Минздрава России. Работа выполнена с использованием оборудования ЦКП «Протеомный анализ», поддержанного финансированием Минобрнауки России (соглашение № 075-15-2021-691).The study was carried out within the framework of the state assignment (No. AAAA-A18-118030790008-7) of Minzdrav of Russia. The study was carried out using the equipment of the Center for Collective Use «Proteomic Analysis», supported by funding from the Russian Ministry of Education and Science (agreement No. 075-15-2021-691).ReferencesLiu H., Shi S., Gao J., Guo J., Li M., Wang L. Analysis of risk factors associated with breast cancer in women: a systematic review and meta-analysis. Transl. Cancer Res. 2022;11(5):1344–1353. doi: 10.21037/tcr22-193Liu H., Shi S., Gao J., Guo J., Li M., Wang L. Analysis of risk factors associated with breast cancer in women: a systematic review and meta-analysis. Transl. Cancer Res. 2022;11(5):1344–1353. doi: 10.21037/tcr22-193Roman M., Louro J., Posso M., Vidal C., Bargallo X., Vazquez I., Quintana M., Alcantara R., Saladie F., Del Riego J., … On Behalf Of The Bele And Iris Study Groups. Long-term risk of breast cancer after diagnosis of benign breast disease by screening mammography. Int. J. Environ. Res. Public. Health. 2022;19(5):2625. doi: 10.3390/ijerph19052625Roman M., Louro J., Posso M., Vidal C., Bargallo X., Vazquez I., Quintana M., Alcantara R., Saladie F., Del Riego J., … On Behalf Of The Bele And Iris Study Groups. Long-term risk of breast cancer after diagnosis of benign breast disease by screening mammography. Int. J. Environ. Res. Public. Health. 2022;19(5):2625. doi: 10.3390/ijerph19052625Kim S., Xuan T., Song H., Ryu S., Chang Y., Park B. Mammographic breast density, benign breast disease, and subsequent breast cancer risk in 3.9 million Korean women. Radiology. 2022;304(3):534–541. doi: 10.1148/radiol.212727Kim S., Xuan T., Song H., Ryu S., Chang Y., Park B. Mammographic breast density, benign breast disease, and subsequent breast cancer risk in 3.9 million Korean women. Radiology. 2022;304(3):534–541. doi: 10.1148/radiol.212727Salamat F., Niakan B., Keshtkar A., Rafiei E., Zendehdel M. Subtypes of benign breast disease as a risk factor of breast cancer: a systematic review and meta analyses. Iran. J. Med. Sci. 2018;43(4):355–364.Salamat F., Niakan B., Keshtkar A., Rafiei E., Zendehdel M. Subtypes of benign breast disease as a risk factor of breast cancer: a systematic review and meta analyses. Iran. J. Med. Sci. 2018;43(4):355–364.Posso M., Alcantara R., Vazquez I., Comerma L., Bare M., Louro J., Quintana M., Román M., MarcosGragera R., Vernet-Tomas M., … BELE study group. Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening. Eur. Radiol. 2022;32(1):621– 629. doi: 10.1007/s00330-021-08118-yPosso M., Alcantara R., Vazquez I., Comerma L., Bare M., Louro J., Quintana M., Román M., MarcosGragera R., Vernet-Tomas M., … BELE study group. Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening. Eur. Radiol. 2022;32(1):621– 629. doi: 10.1007/s00330-021-08118-yVisscher D.W., Nassar A., Degnim A.C., Frost M.H., Vierkant R., Frank R., Tarabishy Y., Radisky D., Hartmann L. Sclerosing adenosis and risk of breast cancer. Breast Cancer Res. Treat. 2014;44(1):205– 212. doi: 10.1007/s10549-014-2862-5Visscher D.W., Nassar A., Degnim A.C., Frost M.H., Vierkant R., Frank R., Tarabishy Y., Radisky D., Hartmann L. Sclerosing adenosis and risk of breast cancer. Breast Cancer Res. Treat. 2014;44(1):205– 212. doi: 10.1007/s10549-014-2862-5Aroner S.A., Collins L.C., Connolly J.L., Colditz G., Schnitt S., Rosner B., Hankinson S., Tamimi R. Radial scars and subsequent breast cancer risk: results from the Nurses’ Health Studies. Breast Cancer Res. Treat. 2013;139(1):277–285. doi: 10.1007/s10549-013-2535-9Aroner S.A., Collins L.C., Connolly J.L., Colditz G., Schnitt S., Rosner B., Hankinson S., Tamimi R. Radial scars and subsequent breast cancer risk: results from the Nurses’ Health Studies. Breast Cancer Res. Treat. 2013;139(1):277–285. doi: 10.1007/s10549-013-2535-9Castells X., Domingo L., Corominas J.M., ToraRocamora I., Quintana M., Bare M., Vidal C., Natal C., Sanchez M., Saladie F., … Sala M. Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population based screening program. Breast Cancer Res. Treat. 2015;149(1):237–244. doi: 10.1007/s10549-014-3208-zCastells X., Domingo L., Corominas J.M., ToraRocamora I., Quintana M., Bare M., Vidal C., Natal C., Sanchez M., Saladie F., … Sala M. Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population based screening program. Breast Cancer Res. Treat. 2015;149(1):237–244. doi: 10.1007/s10549-014-3208-zMendez M.J., Hoffman M.J., Cherry E.M., Lemmon C., Weinberg S. Cell fate forecasting: a data-assimilation approach to predict epithelial-mesenchymal transition. Biophys. J. 2020;118(7):1749–1768. doi: 10.1016/j.bpj.2020.02.011Mendez M.J., Hoffman M.J., Cherry E.M., Lemmon C., Weinberg S. Cell fate forecasting: a data-assimilation approach to predict epithelial-mesenchymal transition. Biophys. J. 2020;118(7):1749–1768. doi: 10.1016/j.bpj.2020.02.011Prieto-Garcia E., Diaz-Garcia C.V., GarciaRuiz I., Agullo-Ortuno T. Epithelial-to-mesenchymal transition in tumor progression. Med. Oncol. 2017;34(7):122. doi: 10.1007/s12032-017-0980-8Prieto-Garcia E., Diaz-Garcia C.V., GarciaRuiz I., Agullo-Ortuno T. Epithelial-to-mesenchymal transition in tumor progression. Med. Oncol. 2017;34(7):122. doi: 10.1007/s12032-017-0980-8Sung J.Y., Cheong J.H. Pan-cancer analysis reveals distinct metabolic reprogramming in different epithelial-mesenchymal transition activity states. Cancers (Basel). 2021;13(8):1778. doi: 10.3390/cancers13081778Sung J.Y., Cheong J.H. Pan-cancer analysis reveals distinct metabolic reprogramming in different epithelial-mesenchymal transition activity states. Cancers (Basel). 2021;13(8):1778. doi: 10.3390/cancers13081778Zhu X., Chen L., Huang B., Wang Y., Ji L., Wu J., Di G., Liu G., Yu K., Shao Z., Wang Z. The prognostic and predictive potential of Ki-67 in triplenegative breast cancer. Sci. Rep. 2020;10(1):225. doi: 10.1038/s41598-019-57094-3Zhu X., Chen L., Huang B., Wang Y., Ji L., Wu J., Di G., Liu G., Yu K., Shao Z., Wang Z. The prognostic and predictive potential of Ki-67 in triplenegative breast cancer. Sci. Rep. 2020;10(1):225. doi: 10.1038/s41598-019-57094-3Ortiz A.B., Garcia D., Vicente Y., Palka M., Bellas C., Martin P. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. PLoS One. 2017;12(11):e0188068. doi: 10.1371/journal.pone.0188068Ortiz A.B., Garcia D., Vicente Y., Palka M., Bellas C., Martin P. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. PLoS One. 2017;12(11):e0188068. doi: 10.1371/journal.pone.0188068Thulin A., Ringvall M., Dimberg A., Karehed K., Vaisanen T., Vaisanen M., Hamad O., Wang J., Bjerkvig R., Nilsson B., … Olsson A. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycopro tein. Mol. Cancer Res. 2009;7(11):1792–1802. doi: 10.1158/1541-7786.MCR-09-0094Thulin A., Ringvall M., Dimberg A., Karehed K., Vaisanen T., Vaisanen M., Hamad O., Wang J., Bjerkvig R., Nilsson B., … Olsson A. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycopro tein. Mol. Cancer Res. 2009;7(11):1792–1802. doi: 10.1158/1541-7786.MCR-09-0094Eissa S., Azzazy H., Matboli M., Shawky S., Said H., Anous F. The prognostic value of histidinerich glycoprotein RNA in breast tissue using unmodified gold nanoparticles assay. Appl. Biochem. Biotechnol. 2014;174(2):751–761. doi: 10.1007/s12010-014-1085-xEissa S., Azzazy H., Matboli M., Shawky S., Said H., Anous F. The prognostic value of histidinerich glycoprotein RNA in breast tissue using unmodified gold nanoparticles assay. Appl. Biochem. Biotechnol. 2014;174(2):751–761. doi: 10.1007/s12010-014-1085-xCedervall J., Zhang Y., Ringvall M., Thulin A., Moustakas A., Jahnen-Dechent W., Siegbahn A., Olsson A. HRG regulates tumor progression, epithelial to mesenchymal transition and metastasis via plateletinduced signaling in the pre-tumorigenic microenvironment. Angiogenesis. 2013;16(4):889–902. doi: 10.1007/s10456-013-9363-8Cedervall J., Zhang Y., Ringvall M., Thulin A., Moustakas A., Jahnen-Dechent W., Siegbahn A., Olsson A. HRG regulates tumor progression, epithelial to mesenchymal transition and metastasis via plateletinduced signaling in the pre-tumorigenic microenvironment. Angiogenesis. 2013;16(4):889–902. doi: 10.1007/s10456-013-9363-8Johnson L.D., Goubran H.A., Kotb R. Histidine rich glycoprotein and cancer: a multi-faceted relationship. Anticancer Res. 2014;34(2):593–603.Johnson L.D., Goubran H.A., Kotb R. Histidine rich glycoprotein and cancer: a multi-faceted relationship. Anticancer Res. 2014;34(2):593–603.Prieto-Garcia E., Diaz-Garcia C.V., Garcia-Ruiz I., Agullo-Ortuno T. Epithelial-to-mesenchymal transition in tumor progression. Med. Oncol. 2017;34(7):122. doi: 10.1007/s12032-017-0980-8Prieto-Garcia E., Diaz-Garcia C.V., Garcia-Ruiz I., Agullo-Ortuno T. Epithelial-to-mesenchymal transition in tumor progression. Med. Oncol. 2017;34(7):122. doi: 10.1007/s12032-017-0980-8Canel M., Serrels A., Frame M.C., Brunton V. E-cadherin-integrin crosstalk in cancer invasion and metastasis, J. Cell. Sci. 2013;126(Pt 2):393–401. doi: 10.1242/jcs.100115Canel M., Serrels A., Frame M.C., Brunton V. E-cadherin-integrin crosstalk in cancer invasion and metastasis, J. Cell. Sci. 2013;126(Pt 2):393–401. doi: 10.1242/jcs.100115Nazemi M., Rainero E. Cross-talk between the tumor microenvironment, extracellular matrix, and cell metabolism in cancer. Front. Oncol. 2020;10:239. doi: 10.3389/fonc.2020.00239Nazemi M., Rainero E. Cross-talk between the tumor microenvironment, extracellular matrix, and cell metabolism in cancer. Front. Oncol. 2020;10:239. doi: 10.3389/fonc.2020.00239

The authors declare that there are no conflicts of interest present.